Aurinia Pharmaceuticals Inc. (AUPH) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Edmonton, BC, Canada. El CEO actual es Kevin C. Tang.
AUPH tiene fecha de IPO 2014-09-03, 130 empleados a tiempo completo, cotiza en el NASDAQ Global Market, una capitalización de mercado de $2.13B.
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
